Full-Time

Staff Accountant

Posted on 8/22/2025

Syndax

Syndax

201-500 employees

Biopharmaceutical company developing oncology therapies

Compensation Overview

$80k - $95k/yr

+ Equity Offering + Annual Target Bonuses

New York, NY, USA

In Person

Category
Accounting (2)
,
Required Skills
Excel/Numbers/Sheets
Requirements
  • Bachelor’s degree in Accounting or Finance
  • 1-2 years of relevant experience
  • Understanding of US GAAP and internal controls
  • Excellent organizational, analytical, and problem-solving skills
  • Strong communication skills with the ability to work effectively in a collaborative environment
  • Self-starter with the ability to manage multiple priorities and meet deadlines
  • Proficient in Excel
Responsibilities
  • Preparing journal entries, analyses, and account reconciliations and assisting with monthly close processes for areas assigned
  • Preparation of all workpapers, and deliverables related to various accounting areas including cash, prepaids, leases, accruals, and fixed assets
  • Generating ad-hoc reports and statements for internal use, as needed
  • Ensure documentation/support created of all work performed is clear, concise, and adheres to internal control policies and procedures
  • Support quarterly and annual financial audits
  • Support internal control over financial reporting audits
  • Prepare quarterly flux analysis of the balance sheet and income statement
  • Support month-end and quarter-end close process, including preparation of financial reporting support schedules
  • Assists procure to pay process in entering invoices and purchase orders
Desired Qualifications
  • Public accounting and/or life sciences experience preferred but not required
  • Experience with NetSuite preferred but not required

Syndax Pharmaceuticals focuses on developing therapies for cancer. Its work centers on researching, testing through clinical trials, and commercializing cancer drugs, with an emphasis on difficult-to-treat cancers such as HR+ HER2- breast cancer. The company’s lead asset is Entinostat, which is being studied in combination with Exemestane for HR+ HER2- breast cancer; results from these trials will influence its growth and market position. Syndax funds its R&D and operations through capital raises and potential licensing or partnerships, and generates revenue by selling approved medicines. Its goal is to bring new cancer treatments to patients who have limited options by advancing promising oncology therapies and securing successful regulatory approvals and partnerships to scale those therapies.

Company Size

201-500

Company Stage

IPO

Headquarters

Waltham, Massachusetts

Founded

2005

Simplify Jobs

Simplify's Take

What believers are saying

  • Revuforj generated $48.9M Q1 2026 revenue, up 144% YoY, with NPM1 label tripling addressable patients.
  • Niktimvo drove $55.1M Incyte sales in Q1 2026, yielding $15.9M collaboration revenue for Syndax.
  • Axatilimab Phase 2 IPF topline data due Q4 2026 targets $1B chronic GVHD expansion opportunity.

What critics are saying

  • Revuforj revenue fluctuates 15% quarterly from high transplant pauses in leukemia patients.
  • Incyte controls Niktimvo pricing and promotion, risking 50% profit-share cut by 2028.
  • E2112 Phase 3 entinostat trial fails primary endpoint in 12-18 months, collapsing HDAC pipeline.

What makes Syndax unique

  • Syndax pioneered Revuforj as first FDA-approved menin inhibitor for NPM1-mutated and KMT2A-rearranged acute leukemias.
  • Niktimvo delivers first-in-class CSF-1R inhibition for chronic graft-versus-host disease via Incyte partnership.
  • Entinostat selectively targets class I HDAC isoforms to reverse hormonal resistance in HR+/HER2- breast cancer.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

2%

1 year growth

12%

2 year growth

18%
Yahoo Finance
Mar 22nd, 2026
DAFNA Capital trims Syndax Pharmaceuticals stake by $3.9M despite 72% stock surge

DAFNA Capital Management sold 222,847 shares of Syndax Pharmaceuticals in the fourth quarter of 2025, with an estimated transaction value of $3.89 million, according to a 17 February 2026 SEC filing. The sale reduced Syndax's weighting in DAFNA's portfolio from 1.90% to 1.36% of its $430.52 million in reportable assets. Despite the trim, Syndax shares have surged 72% over the past year to $24.23, significantly outperforming the S&P 500's 15% gain. Syndax, a clinical-stage biopharmaceutical company focused on oncology therapies, generated $172.4 million in revenue over the trailing twelve months whilst posting a net loss of $285.4 million. The company is developing treatments including SNDX-5613 for acute myeloid leukaemia and axatilimab for chronic graft versus host disease.

Yahoo Finance
Mar 21st, 2026
Biotech Syndax sees $8M stake cut by Kynam, but remains fund's third-largest holding at 11%

Kynam Capital Management sold 469,041 shares of Syndax Pharmaceuticals valued at approximately $8.18 million during the fourth quarter of 2025, according to a Securities and Exchange Commission filing dated 17 February 2026. Despite the sale, the fund retained a significant stake, with Syndax remaining its third-largest holding at 10.81% of reportable assets. Syndax shares have surged 72% over the past year, reaching $24.23, substantially outperforming the S&P 500's 15% gain. The clinical-stage biotechnology company generated $172 million in revenue last year, driven by uptake of recently launched therapies including Revuforj and its Niktimvo collaboration. However, the company posted a $285 million net loss for the year amid elevated research and development costs. Kynam's partial sale appears to be portfolio rebalancing rather than a loss of confidence in the biotech firm.

AOL
Mar 13th, 2026
Cancer drug maker with $172M revenue draws $6.5M investment from Sphera Funds

Sphera Funds Management purchased 374,847 shares of Syndax Pharmaceuticals in the fourth quarter, an estimated $6.54 million investment based on quarterly average pricing. The acquisition brought Sphera's total holding to 762,563 shares valued at $16.02 million, representing approximately 3% of its assets under management. Syndax Pharmaceuticals, a biotechnology company developing cancer therapies, reported $172.4 million in revenue for 2025, up sharply from $23.7 million the previous year. The growth was driven by two approved therapies: Revuforj, which generated $124.8 million in full-year revenue, and Niktimvo, developed with Incyte, which delivered $151.6 million in net sales. Shares have surged 83% over the past year, significantly outperforming the S&P 500's roughly 20% gain.

Yahoo Finance
Mar 2nd, 2026
Syndax sees $277M in sales from Revuforj and Niktimvo, eyes $1B opportunity in chronic GVHD

Syndax Pharmaceuticals reported strong commercial performance for its two flagship cancer drugs at the Guggenheim biotech conference on 15 February. Chief Executive Officer Michael Metzger said the company started 2026 on solid footing with significant progress on clinical milestones. Revuforj generated $125 million in net sales during the first 11 months, driven by penetration in acute myeloid leukaemia treatment. Niktimvo achieved $152 million in sales, with both products showing quarter-over-quarter growth. The company sees significant opportunity in chronic graft-versus-host disease treatment, targeting up to 17,000 patients. Syndax estimates potential third-line plus sales of up to $1 billion. The company has a strategic collaboration with Incyte to co-promote Niktimvo.

Yahoo Finance
Feb 27th, 2026
Syndax Pharmaceuticals reports Revuforj revenue of $44.2M in Q4 after label expansion

Syndax Pharmaceuticals reported Revuforj generated $124.8 million in net revenue during 2025, its first full year on the market. Fourth-quarter revenue reached $44.2 million, driven by growth in KMT2A-rearranged acute myeloid leukaemia and increasing uptake in NPM1-mutated AML following an expanded FDA label in late October. Chief Commercial Officer Steve Closter said the company is approaching 50% penetration of the KMT2A incident population. The NPM1 indication triples the addressable patient population to approximately 3,000 patients annually, with formulary coverage complete at major payers within four months of approval. Management indicated NPM1 patients represented roughly 30% of new starts in the fourth quarter and expect the indication to grow towards a 50/50 split with KMT2A given the larger patient population.

INACTIVE